Answers are grounded in this paper and cite their sources.
Background To compare the effectiveness, cost, and safety of four regimens recommended by the World Health Organization (WHO) for rifampicin resistance/multidrug-resistance tuberculosis (RR/MDR-TB) Treatment in Eastern China.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: